Sanctura XR NDA Filing On Target For Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Indevus reports Phase III trial results confirming earlier data demonstrating the efficacy of the once-daily overactive bladder treatment.
You may also be interested in...
Sanctura Once-Daily NDA Touts “Landmark Tolerability”
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
Sanctura Once-Daily NDA Touts “Landmark Tolerability”
Indevus will position the XR version of its incontinence therapy based on its low incidence of dry mouth.
Sanctura XR Could Quench Indevus’ Thirst For Once-Daily Incontinence Therapy
Results from the first of two Phase III trials of trospium extended-release report 8.7% incidence of dry mouth, compared to 20.1% for twice-daily Sanctura.